NASDAQ:QURE
uniQure N.V.
- Stock
locale
Netherlands
market
STOCKSindustry
Biotechnologywebsite
www.uniqure.comipo date
Feb 05, 2014
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical stud...Show More
Earnings
Earnings per Share (Estimate*)
Revenue (Estimate*)
*Estimate based on analyst consensus